Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?

What Triggered The Recent Surge?

The direct catalyst was the successful clinical trial of the experimental mRNA cancer vaccine in collaboration with Moderna (MRNA). This achievement exhibited significant effectiveness, resulting in a notable increase in buying activity due to immediate revenue potential in oncology. However, yesterday’s announcement merely confirms a larger strategy. The true factor driving the annual gain is how systematically Merck addressed the principal concern that has kept shareholders awake at night: What will transpire after the KEYTRUDA patent expiration?

For numerous years, the approaching loss of exclusivity for the blockbuster drug KEYTRUDA posed a substantial burden. The company’s leadership responded to this anxiety with a consistent stream of clinical and regulatory successes. The pipeline has produced concrete outcomes, transforming the company from one on the brink of a patent expiration to one that is constructing a dependable pathway for steady earnings growth.

What Has The Pipeline Actually Achieved?

The pivotal event was the FDA’s approval of LIPFENDRA. As the first oral PCSK9 inhibitor for individuals with high cholesterol, it disrupts a market that has been primarily reliant on injectables. Clinical evidence indicates that this daily pill can reduce LDL cholesterol by as much as 60% when used in conjunction with a statin. In addition to the recent mRNA cancer vaccine data, Merck also reported favorable Phase III results for sac-TMT in endometrial cancer and tulisokibart for ulcerative colitis. Growing uncertainties in the pipeline have been replaced by confirmed successes, demonstrating that the research engine continues to be highly productive.

How Substantial Is This New Commercial Plan?

With clinical data solidifying, management has finally outlined future expectations. They estimate a pipeline with over $70 billion in commercial potential spread across more than 20 new products. For a market fixated on the forthcoming KEYTRUDA revenue gap, this figure serves as a compelling counter-narrative. The significant stock revaluation indicates that Wall Street now confidently endorses this projection.

Is The New Valuation Warranted When Compared To Competitors?

Valuation serves as the ultimate test of this shift. All forward-looking peer valuations are based on consensus estimates for 2027 on an adjusted EPS basis. At $152 per share against anticipated adjusted earnings of $9.56, Merck is trading at a mere 16x forward earnings. When compared across the peer landscape, while Pfizer (PFE) is priced at a lowly 9.6x multiple and AbbVie (ABBV) at 16.4x, higher-growth competitors command significant premiums. Johnson & Johnson (JNJ) trades at 21.5x forward earnings, while Eli Lilly (LLY) commands 27x. Even with an over 73% rise in the past twelve months, Merck’s 16x multiple underlines that the stock is still undervalued relative to top-tier competitors, suggesting more upside potential if they maintain performance.

Can Merck Successfully Market LIPFENDRA?

Acquiring approval for a drug is one challenge, but achieving widespread prescriptions is quite another. The track record of injectable PCSK9 inhibitors has been marked by slow adoption rates, particularly within primary care environments. Analysts are scrutinizing the speed of initial access and whether a significant outcomes trial will act as the commercial turning point. Merck is betting vigorously on total market expansion rather than merely capturing existing market share.

Has The Sales Strategy Been Validated?

The risks of clinical development have largely diminished, replaced by the less predictable risks associated with global commercial execution. The foundational science behind the mRNA cancer vaccine has been validated by late-stage clinical findings, while the broader pipeline continues to receive formal approvals from regulators. Now, the company must flawlessly execute its commercialization strategy to substantiate the new valuation.

The Final Assessment

Investors should consider Merck not merely as a company facing a looming patent expiration, but rather as a de-risked commercial leader with clear visibility into its pipeline. In our opinion, Merck remains fundamentally undervalued at 16 times 2027 adjusted earnings compared to its peer group, presenting an appealing risk-reward profile as operational execution unfolds.